Pluri (NASDAQ:PLUR – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.
Volatility and Risk
Pluri has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Pluri and Biomea Fusion, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 1 | 0 | 1 | 0 | 2.00 |
| Biomea Fusion | 1 | 1 | 7 | 1 | 2.80 |
Valuation and Earnings
This table compares Pluri and Biomea Fusion”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $1.34 million | 22.88 | -$22.58 million | ($4.92) | -0.62 |
| Biomea Fusion | N/A | N/A | -$138.43 million | ($2.39) | -0.47 |
Pluri has higher revenue and earnings than Biomea Fusion. Pluri is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
16.6% of Pluri shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 25.9% of Pluri shares are held by insiders. Comparatively, 18.4% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Pluri and Biomea Fusion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -1,890.59% | N/A | -99.68% |
| Biomea Fusion | N/A | -310.15% | -145.38% |
Summary
Biomea Fusion beats Pluri on 8 of the 14 factors compared between the two stocks.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
About Biomea Fusion
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
